# Burden and outcomes of pediatric acute respiratory distress syndrome among children with sepsis: a cohort study

**Authors:** Nawras Asiri, Lama Khaled Bahatheq, Naila Shaheen, Yasser M. Kazzaz

PMC · DOI: 10.3389/fped.2026.1762030 · Frontiers in Pediatrics · 2026-02-16

## TL;DR

This study finds that pediatric acute respiratory distress syndrome (PARDS) is common in children with sepsis and is linked to severe illness, higher care needs, and increased mortality.

## Contribution

The study identifies PARDS as a frequent and severe complication in pediatric sepsis, comparing pulmonary and extrapulmonary PARDS phenotypes and their outcomes.

## Key findings

- PARDS occurred in 57.7% of children with sepsis and was associated with higher mortality (36.6% vs. 7.6%).
- Children with PARDS required more mechanical ventilation, vasoactive support, and renal replacement therapy.
- Extrapulmonary PARDS showed a higher inflammatory burden and more bacterial infections compared to pulmonary PARDS.

## Abstract

To determine the prevalence, clinical characteristics, outcomes, and mortality risk factors of pediatric acute respiratory distress syndrome (PARDS) among children with sepsis, and to compare pulmonary and extrapulmonary PARDS phenotypes.

This retrospective cohort study analyzed children aged 0–14 years with Phoenix-defined sepsis admitted to a tertiary pediatric intensive care unit between 2015 and 2023. PARDS was defined according to PALICC-2 criteria. Demographics, illness severity, microbiology, organ support requirements, and clinical outcomes were compared between children with and without PARDS and between pulmonary and extrapulmonary phenotypes. Multivariable logistic regression models were used to identify independent predictors of mortality.

Among 279 children with Phoenix-defined sepsis, 161 (57.7%) developed PARDS. Children with PARDS were younger, had higher PELOD-2 and Phoenix severity scores, and required significantly more mechanical ventilation, vasoactive support, and renal replacement therapy compared with those without PARDS. Mortality was substantially higher in the PARDS cohort (36.6% vs. 7.6%). Model-estimated mortality probability increased stepwise with worsening PARDS severity and was highest among children with both septic shock and severe PARDS. Pulmonary PARDS accounted for two-thirds of cases, whereas extrapulmonary PARDS demonstrated a higher inflammatory burden and more bacterial infections. In adjusted analyses, the presence of PARDS, higher PELOD-2 score, and greater cumulative fluid balance were independently associated with mortality.

PARDS is a common and common complication associated with high risk of pediatric sepsis, associated with severe organ dysfunction, increased support requirements, and markedly elevated mortality. These findings underscore the need for multicenter validation to confirm the epidemiology and risk factors of sepsis-associated PARDS and to guide earlier recognition and management approaches for this high-risk population.

## Linked entities

- **Diseases:** acute respiratory distress syndrome (MONDO:0006502), PARDS (MONDO:0100131)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, UROD (uroporphyrinogen decarboxylase) [NCBI Gene 7389] {aka PCT, UPD}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}
- **Diseases:** Sepsis (MESH:D018805), septic shock (MESH:D012772), chest imaging (MESH:C564543), neuromuscular disease (MESH:D009468), bacterial infections (MESH:D001424), renal disease (MESH:D007674), aspiration (MESH:D011015), cardiac failure (MESH:D006333), bronchopulmonary dysplasia (MESH:D001997), P (MESH:D002972), cardiovascular dysfunction (MESH:D002318), infection (MESH:D007239), chronic renal failure (MESH:D007676), gastrointestinal disease (MESH:D005767), immunodeficiency (MESH:D007153), Mortality (MESH:D003643), hematological disorders (MESH:D006402), epilepsy (MESH:D004827), hypoxemia (MESH:D000860), metabolic disorders (MESH:D008659), ARDS (MESH:D012128), Pneumonia (MESH:D011014), congenital or acquired (MESH:D000163), opacities (MESH:D003318), hypoxemic respiratory failure (MESH:D012131), PELOD-2 (MESH:D009102), cystic fibrosis (MESH:D003550), Acute Lung Injury (MESH:D055371), inflammatory lung injury (MESH:D055370), asthma (MESH:D001249), multiorgan failure (MESH:D051437), respiratory disease (MESH:D012140), fluid (MESH:D002559), inflammation (MESH:D007249), multiorgan injury (MESH:D014947), neoplastic disease (MESH:D004194), fluid overload (MESH:D019190)
- **Chemicals:** reactive oxygen species (MESH:D017382), Phoenix (-), oxygen (MESH:D010100)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950753/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950753/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950753/full.md

---
Source: https://tomesphere.com/paper/PMC12950753